Clear Cell Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CLR003 MIFTS: 55	Clear Cell Adenocarcinoma Categories: Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Clear Cell Adenocarcinoma

MalaCards integrated aliases for Clear Cell Adenocarcinoma:

Name: Clear Cell Adenocarcinoma ¹² ¹⁵

Mesonephroma ¹² ⁴⁴ ⁷³

Water-Clear Cell Adenocarcinoma ¹² ⁷³

Adenocarcinoma, Clear Cell ⁴⁴ ⁷³

Mesonephroid Clear Cell Carcinoma ¹²

Water-Clear Cell Carcinoma ¹²

Adenocarcinoma Clear Cell ⁵⁵

Mesonephroma, Malignant ¹²

Malignant Mesonephroma ¹²

Wolffian Duct Neoplasm ¹²

Mesonephric Tumor ⁷³

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:4468

MeSH ⁴⁴ D008649 D018262

NCIt ⁵⁰ C36815 C3766 C4072 more

SNOMED-CT ⁶⁸ 2221008 30546008 80727009

UMLS ⁷³ C0025490 C0206681 C0334322 more

Sources

Summaries for Clear Cell Adenocarcinoma

Disease Ontology : ¹² An adenocarcinoma that derives from epithelial cells which have clear cytoplasm.

MalaCards based summary : Clear Cell Adenocarcinoma, also known as mesonephroma, is related to urethra clear cell adenocarcinoma and ovarian clear cell adenocarcinoma. An important gene associated with Clear Cell Adenocarcinoma is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Developmental Biology and Endometrial cancer. The drugs Carboplatin and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include cervix, ovary and colon, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : ⁷⁶ Clear-cell adenocarcinoma is a type of adenocarcinoma that shows clear... more...

Sources

Related Diseases for Clear Cell Adenocarcinoma

Diseases related to Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)

#	Related Disease	Score	Top Affiliating Genes
1	urethra clear cell adenocarcinoma	34.1	AMACR KLK3 SMAD4
2	ovarian clear cell adenocarcinoma	33.7	ARID1A HNF1B SMAD3
3	clear cell adenofibroma	30.2	ARID1A KRT7
4	endodermal sinus tumor	30.1	KLK3 MUC16
5	urethral diverticulum	30.1	AMACR KLK3 KRT7 PAX8
6	vulva adenocarcinoma	29.9	KRT20 KRT7
7	urethra adenocarcinoma	29.9	AMACR KLK3 SMAD4
8	endosalpingiosis	29.8	KRT7 PAX8
9	ovary adenocarcinoma	29.7	ARID1A HNF1B KRT7
10	ovarian cancer 1	29.6	ARID1A HNF1B KRT7 PAX8
11	nephrogenic adenoma	29.6	AMACR KLK3 KRT7 PAX2 PAX8
12	endocervical adenocarcinoma	29.5	KRT20 KRT7 PAX2 PAX8
13	clear cell renal cell carcinoma	29.4	KRT7 PAX2 PAX8
14	renal cell carcinoma, nonpapillary	28.8	AMACR HNF1B KRT20 KRT7 PAX2 PAX8
15	bladder clear cell adenocarcinoma	12.5
16	bile duct clear cell adenocarcinoma	12.5
17	clear cell adenocarcinoma of the ovary	12.5
18	cervical clear cell adenocarcinoma	12.4
19	endometrial clear cell adenocarcinoma	12.4
20	fallopian tube clear cell adenocarcinoma	12.4
21	uterine ligament clear cell adenocarcinoma	12.2
22	ampulla of vater clear cell adenocarcinoma	12.2
23	bladder tubulo-cystic clear cell adenocarcinoma	12.2
24	bladder papillary clear cell adenocarcinoma	12.2
25	bladder diffuse clear cell adenocarcinoma	12.2
26	diethylstilbestrol syndrome	11.4
27	wolffian duct adenoma	11.3
28	epithelial-myoepithelial carcinoma	11.2
29	multilocular cystic renal neoplasm of low malignant potential	11.2
30	adenocarcinoma	11.1
31	endometriosis	10.6
32	adenofibroma	10.2
33	adenoma	10.2
34	seminal vesicle tumor	10.2	KLK3 KRT7
35	prostate squamous cell carcinoma	10.2	KLK3 KRT7
36	rete testis adenocarcinoma	10.2	KLK3 KRT20
37	oligomeganephronia	10.2	HNF1B PAX2
38	cystic basal cell carcinoma	10.2	KRT20 KRT7
39	hypertrophic scars	10.2	SMAD2 SMAD3
40	transverse colon cancer	10.2	KRT20 KRT7
41	appendix adenocarcinoma	10.2	KRT20 KRT7
42	malignant syringoma	10.2	KRT20 KRT7
43	glandular cystitis	10.1	KRT20 KRT7
44	papillary transitional carcinoma	10.1	KRT20 KRT7
45	eyelid carcinoma	10.1	KRT20 KRT7
46	large intestine adenocarcinoma	10.1	KRT20 KRT7
47	linitis plastica	10.1	KRT20 KRT7
48	lung acinar adenocarcinoma	10.1	KRT20 KRT7
49	small cell carcinoma of the bladder	10.1	KRT20 KRT7
50	adenoid squamous cell carcinoma	10.1	KRT20 KRT7

Graphical network of the top 20 diseases related to Clear Cell Adenocarcinoma:

Sources

Symptoms & Phenotypes for Clear Cell Adenocarcinoma

GenomeRNAi Phenotypes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

²⁶ (show all 29)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-107	9.87	SMAD4
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-11	9.87	SMAD4
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-114	9.87	ARID1A
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-157	9.87	HNF1B
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-166	9.87	PAX8
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-168	9.87	ARID1A
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-176	9.87	ARID1A
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-177	9.87	HNF1B
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-185	9.87	HNF1B
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-186	9.87	ARID1A
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-190	9.87	ARID1A
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-195	9.87	SMAD4
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-21	9.87	SMAD4
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-214	9.87	HNF1B
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-25	9.87	PAX8 SMAD4
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-3	9.87	PAX8
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-41	9.87	PAX8
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-42	9.87	SMAD4
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	9.87	ARID1A HNF1B PAX8 SMAD4
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-46	9.87	SMAD4
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-49	9.87	HNF1B
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-5	9.87	HNF1B
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-54	9.87	SMAD4
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-73	9.87	ARID1A SMAD4
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-74	9.87	SMAD4
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-8	9.87	HNF1B
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-80	9.87	HNF1B
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-81	9.87	PAX8 SMAD4
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-93	9.87	PAX8

MGI Mouse Phenotypes related to Clear Cell Adenocarcinoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.08	ARID1A KRT7 PAX2 PAX8 PTHLH SMAD2
2	homeostasis/metabolism	MP:0005376	10.02	AMACR ARID1A HNF1B KRT7 PAX8 PTHLH
3	endocrine/exocrine gland	MP:0005379	10.01	ARID1A HNF1B PAX2 PAX8 PTHLH SMAD2
4	embryo	MP:0005380	9.98	ARID1A HNF1B PAX2 PAX8 SMAD2 SMAD3
5	craniofacial	MP:0005382	9.93	ARID1A PAX8 PTHLH SMAD2 SMAD3 SMAD4
6	liver/biliary system	MP:0005370	9.8	AMACR HNF1B PTHLH SMAD2 SMAD3 SMAD4
7	renal/urinary system	MP:0005367	9.7	HNF1B KRT7 PAX2 PAX8 PTHLH SMAD3
8	neoplasm	MP:0002006	9.65	ARID1A PTHLH SMAD2 SMAD3 SMAD4
9	reproductive system	MP:0005389	9.5	ARID1A PAX2 PAX8 PTHLH SMAD2 SMAD3
10	vision/eye	MP:0005391	9.1	ARID1A PAX2 PAX8 PTHLH SMAD2 SMAD3

Sources

Drugs & Therapeutics for Clear Cell Adenocarcinoma

Drugs for Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Carboplatin

Approved

Phase 3,Phase 2,Phase 1

41575-94-4

10339178 38904 498142

Doxorubicin

Approved, Investigational

Phase 3,Phase 2,Phase 1

23214-92-8

31703

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2,Phase 1

33069-62-4

36314

Bevacizumab

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

216974-75-3

Lenograstim

Approved, Investigational

Phase 3,Phase 1

135968-09-1

Cisplatin

Approved

Phase 3,Phase 2,Phase 1

15663-27-1

2767 441203 84093

Epirubicin

Approved

Phase 3

56420-45-2

41867

Docetaxel

Approved, Investigational

Phase 3,Phase 2

114977-28-5

148124

Gemcitabine

Approved

Phase 3,Phase 2

95058-81-4

60750

Atezolizumab

Approved, Investigational

Phase 2, Phase 3

1380723-44-3

Olaparib

Approved

Phase 2, Phase 3,Phase 3

763113-22-0

23725625

Topotecan

Approved, Investigational

Phase 2, Phase 3

123948-87-8, 119413-54-6

60700

Metformin

Approved

Phase 2, Phase 3

657-24-9

14219 4091

Glutamic Acid

Approved, Nutraceutical

Phase 3

56-86-0

33032

Doxil

Approved June 1999

Phase 3,Phase 2,Phase 1

31703

Cediranib

Investigational

Phase 2, Phase 3,Phase 3

288383-20-0

9933475

Maleic acid

Experimental

Phase 2, Phase 3,Phase 3

110-16-7

444266

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1

Topoisomerase Inhibitors

Phase 3,Phase 2,Phase 1

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1

Antimetabolites

Phase 3,Phase 2,Phase 1

Immunoglobulin G

Phase 3,Phase 2,Phase 1

Antibodies, Monoclonal

Phase 3,Phase 2,Phase 1

Angiogenesis Inhibitors

Phase 3,Phase 2,Phase 1,Not Applicable

Antibodies

Phase 3,Phase 2,Phase 1

Immunoglobulins

Phase 3,Phase 2,Phase 1

Immunologic Factors

Phase 3,Phase 2,Phase 1,Not Applicable

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2,Phase 1

Endothelial Growth Factors

Phase 3,Phase 2,Phase 1

Antimitotic Agents

Phase 3,Phase 2,Phase 1

Angiogenesis Modulating Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Mitogens

Phase 3,Phase 2,Phase 1

Albumin-Bound Paclitaxel

Phase 3,Phase 2,Phase 1

Adjuvants, Immunologic

Phase 3,Phase 1

Protein Kinase Inhibitors

Phase 2, Phase 3,Phase 3,Phase 1

Antiviral Agents

Phase 3,Phase 2,Phase 1

Anti-Infective Agents

Phase 3,Phase 2,Phase 1

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1

Poly(ADP-ribose) Polymerase Inhibitors

Phase 2, Phase 3,Phase 3,Phase 1

topoisomerase I inhibitors

Phase 2, Phase 3

Carotenoids

Phase 3

Micronutrients

Phase 3,Not Applicable

Trace Elements

Phase 3,Not Applicable

Hypoglycemic Agents

Phase 2, Phase 3

taxane

Phase 3,Not Applicable

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Vinblastine

Approved

Phase 2

865-21-4

241903 13342

Sunitinib

Approved, Investigational

Phase 2,Not Applicable

557795-19-4, 341031-54-7

5329102

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239 406563

Interventional clinical trials:

(show top 50) (show all 104)

#	Name	Status	NCT ID	Phase	Drugs
1	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Completed	NCT00262847	Phase 3	Carboplatin;Paclitaxel
2	Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer	Completed	NCT00003749	Phase 3
3	Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer	Completed	NCT00006011	Phase 3	Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
4	Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer	Completed	NCT00005583	Phase 3	cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
5	Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery	Completed	NCT00002807	Phase 3
6	Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer	Completed	NCT00002493	Phase 3	cisplatin;doxorubicin hydrochloride
7	Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer	Completed	NCT00006027	Phase 3	cisplatin;paclitaxel
8	Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recruiting	NCT02839707	Phase 2, Phase 3	Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
9	Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recruiting	NCT02502266	Phase 2, Phase 3	Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
10	Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recruiting	NCT00719303	Phase 3
11	Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol	Recruiting	NCT02501954	Phase 3	Cisplatin;Carboplatin;Paclitaxel
12	Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer	Recruiting	NCT03422198	Phase 3
13	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Active, not recruiting	NCT00565851	Phase 3	Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
14	Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Active, not recruiting	NCT02446600	Phase 3	Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
15	Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer	Active, not recruiting	NCT00108745	Phase 3	Paclitaxel;Paclitaxel Poliglumex
16	Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer	Active, not recruiting	NCT02065687	Phase 2, Phase 3	Carboplatin;Metformin Hydrochloride;Paclitaxel
17	Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer	Active, not recruiting	NCT00942357	Phase 3	Carboplatin;Cisplatin;Paclitaxel
18	Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer	Active, not recruiting	NCT00807768	Phase 3	Carboplatin;Paclitaxel
19	Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer	Active, not recruiting	NCT00411138	Phase 3	cisplatin;carboplatin;Paclitaxel
20	Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer	Active, not recruiting	NCT01672892	Phase 3
21	Immunochemotherapy for Metastatic Renal Cell Carcinoma	Unknown status	NCT00226798	Phase 2	Capecitabine (Xeloda)
22	Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer	Unknown status	NCT01100359	Phase 2	carboplatin;liposome-encapsulated doxorubicin citrate
23	Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma	Completed	NCT01824615	Phase 2	Sunitinib
24	A Study of ENMD-2076 in Ovarian Clear Cell Cancers	Completed	NCT01914510	Phase 2	ENMD-2076
25	AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib	Completed	NCT00467025	Phase 2	AMG 386;Sorafenib;AMG 386 placebo IV
26	Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney	Completed	NCT00853021	Phase 2
27	Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer	Completed	NCT00416455	Phase 1, Phase 2	ferumoxtran-10
28	Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer	Completed	NCT01196429	Phase 2	Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
29	Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer	Completed	NCT00719264	Phase 2	RAD001(everolimus);interferon alfa-2a;bevacizumab
30	LBH589 Treatment for Refractory Clear Cell Renal Carcinoma	Completed	NCT00550277	Phase 2	LBH589
31	Sunitinib in Metastatic Renal Cancer	Completed	NCT01034878	Phase 2	Sunitinib
32	Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT01011933	Phase 2	Selumetinib
33	Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT00820898	Phase 2	Gemcitabine Hydrochloride
34	High-dose Bevacizumab in Advanced Renal Carcinoma Patients	Completed	NCT00455975	Phase 2	Bevacizumab
35	Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer	Completed	NCT00002562	Phase 2	paclitaxel
36	Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer	Completed	NCT01307631	Phase 2	Akt Inhibitor MK2206
37	Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT01132820	Phase 2	Cediranib Maleate
38	Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT01642082	Phase 2
39	Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT01225887	Phase 2	Nintedanib
40	Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT00888173	Phase 2	Brivanib Alaninate
41	Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer	Completed	NCT01210222	Phase 2
42	Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer	Completed	NCT01005329	Phase 2	Carboplatin;Cisplatin;Paclitaxel
43	Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT00025467	Phase 2	thalidomide
44	S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer	Completed	NCT00003127	Phase 2	amifostine trihydrate;carboplatin;paclitaxel
45	Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer	Completed	NCT00072176	Phase 2	temsirolimus
46	Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer	Completed	NCT00770185	Phase 2	ridaforolimus
47	Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer	Completed	NCT00113373	Phase 2	lapatinib ditosylate
48	Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium	Recruiting	NCT02866370	Phase 2	Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
49	A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas	Recruiting	NCT03405454	Phase 2	durvalumab;standard chemotherapy
50	BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas	Recruiting	NCT03355976	Phase 2	Nivolumab;Ipilimumab

Search NIH Clinical Center for Clear Cell Adenocarcinoma

Cochrane evidence based reviews: mesonephroma

Sources

Genetic Tests for Clear Cell Adenocarcinoma

Sources

Anatomical Context for Clear Cell Adenocarcinoma

MalaCards organs/tissues related to Clear Cell Adenocarcinoma:

⁴¹

Cervix, Ovary, Colon, Prostate, T Cells, Kidney, Lymph Node

Sources

Publications for Clear Cell Adenocarcinoma

Articles related to Clear Cell Adenocarcinoma:

(show top 50) (show all 458)

#	Title	Authors	Year
1	Ovarian Clear Cell Adenofibroma of Low Malignant Potential Developing Into Clear Cell Adenocarcinoma. ( 29551085 )	Yin Z....Heller D.	2018
2	Synchronous occurrence of primary right ovarian endometrioid adenocarcinoma and primary left ovarian clear cell adenocarcinoma: A case report. ( 29979406 )	Zhao L.J....He Y.	2018
3	Clear Cell Adenocarcinoma Arising from Endometriosis in the Groin: Wide Resection and Reconstruction with a Fascia Lata Tensor Muscle Skin Flap. ( 29805826 )	Yoshida S....Kobayashi H.	2018
4	Unusual Features of Clear Cell Adenocarcinoma of the Female Urethra: A Case Report and Literature Review. ( 29977425 )		2018
5	Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma with fetal gut differentiation: a rare case report and literature review. ( 29933751 )		2018
6	Clear cell adenocarcinoma of female urethra: A case report. ( 29888186 )		2018
7	Clear cell adenocarcinoma of the urethra with inguinal lymph node metastases: A rare case report and review of literature. ( 29516944 )		2018
8	Follow-up of Patients with Clear-Cell Adenocarcinoma of the Vagina and Cervix. ( 29719188 )		2018
9	Primary clear cell adenocarcinoma of the pancreas: a case report and literature update. ( 30532559 )	Sun PJ...Cui XJ	2018
10	Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response. ( 30202792 )	Vargas R...Abazeed ME	2018
11	Fairly rare clear cell adenocarcinoma mimicking liver cancer: a case report. ( 30117003 )	Harimoto N...Shirabe K	2018
12	Cervical clear cell adenocarcinoma with an exceptionally low proliferation index: Report of a case. ( 29326971 )	Dandulakis MG...Hagemann IS	2018
13	Three cases of clear-cell adenocarcinoma arising from endometrioma during hormonal treatments. ( 29998468 )	Yoshino O...Saito S	2018
14	Early stage clear cell adenocarcinoma of the colon examined in detail with image-enhanced endoscopy: a case report. ( 30062544 )	Tochio T...Watanabe G	2018
15	Clear Cell Adenocarcinoma of the Urethra in Women: Distinctive MRI Findings for Differentiation From Nonadenocarcinoma and Non-Clear Cell Adenocarcinoma of the Urethra. ( 28140610 )	Kim T.H....Kim S.H.	2017
16	Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up. ( 28689666 )	Huo D....Herbst A.L.	2017
17	Clear cell adenocarcinoma of the cervix in second generation young women who are without maternal exposure to diethylstilbestrol: A case report. ( 28275694 )	Tantitamit T....Rangsiratanakul L.	2017
18	Skin metastases in ovarian clear cell adenocarcinoma: a case report and a review of the literature. ( 29184869 )	Nam G....Kim Y.H.	2017
19	Clear cell adenocarcinoma of cervix in 1-year-old girl without in utero exposure to diethylstilbestrol: an uncommon tumour at an uncommon age and site. ( 28302659 )	Arora A....Husain N.	2017
20	Clear Cell Adenocarcinoma of Female Urethra. ( 28892907 )	Rane S.R....Vishwasrao S.	2017
21	The Prostate in Female? Clear Cell Adenocarcinoma in a Female Urethral Diverticulum. ( 27789300 )	Sadahira T....Nasu Y.	2017
22	Clear Cell Adenocarcinoma of the Female Urethra, Mimicking Cystocele. ( 28280687 )		2017
23	Vesical clear cell adenocarcinoma arising from endometriosis: A mullerian tumor, indistinguishable from ovarian clear cell adenocarcinoma. ( 27660815 )	Miller E.M....Frimer M.	2016
24	A clear cell adenocarcinoma of the gallbladder with hepatoid differentiation: case report and review of literature. ( 27703378 )	Zhang C....Zhao L.	2016
25	Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary. ( 27699033 )	Kato M....Furuya K.	2016
26	Clear Cell Adenocarcinoma of the Female Urethra: Four Case Presentations of a Clinical and Pathological Entity Requiring Radical Surgery. ( 26807736 )	Liedberg F....Johansson M.E.	2016
27	Clear Cell Adenocarcinoma of the Lung Mimicking Clear Cell Renal Cell Carcinoma. ( 29772138 )		2016
28	Clear cell adenocarcinoma of the cervix in a ten-year-old girl without prenatal diethylstilbestrol exposure. ( 27549741 )	Andi Asri AA...A Latiff L	2016
29	Clear cell adenocarcinoma arising from adenomyotic cyst: A case report and literature review. ( 26530432 )	Baba A....Miyauchi J.	2015
30	Combined benign Brenner tumor and clear cell adenocarcinoma of the ovary. ( 26150073 )	Matsumoto H....Kato S.	2015
31	Low Expression of S100P Is Associated With Poor Prognosis in Patients With Clear Cell Adenocarcinoma of the Ovary. ( 26397155 )	Umezaki Y....Yasuhi I.	2015
32	Primary Fallopian Tube Clear Cell Adenocarcinoma in Pregnancy: Case Presentation and Review of the Literature. ( 26090245 )	Malak M....Klam S.	2015
33	Successful radiotherapy for repeated recurrent uterine clear cell adenocarcinoma. ( 26310385 )	Iwashita A....Nakazawa M.	2015
34	High-dose-rate brachytherapy - a novel treatment approach for primary clear cell adenocarcinoma of male urethra. ( 26207115 )		2015
35	Clear cell adenocarcinoma of the urethra: review of the literature. ( 25685552 )		2015
36	A rare case of primary clear-cell adenocarcinoma of the bladder arising from bladder endometriosis. ( 25642923 )		2015
37	Late recurrence in a case of vaginal clear cell adenocarcinoma unrelated to transplacental diethylstilbestrol exposure. ( 26905123 )		2015
38	Clear Cell Adenocarcinoma Arising from Adenofibroma in a Patient with Endometriosis of the Ovary. ( 26498012 )		2015
39	Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma. ( 25658832 )		2015
40	Clear cell adenocarcinoma of the bladder with intravesical cervical invasion. ( 26109625 )	Marchalik D...Venkatesan K	2015
41	Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice. ( 25398420 )	Matsuo Y....Katabuchi H.	2014
42	Mass Spectrometric Analysis of the Phosphorylation Levels of the SWI/SNF Chromatin Remodeling/Tumor Suppressor Proteins ARID1A and Brg1 in Ovarian Clear Cell Adenocarcinoma Cell Lines. ( 25083560 )	Kimura A....Hirano H.	2014
43	Non-diethylstilbestrol exposed vaginal clear cell adenocarcinoma has a common molecular profile with ovarian clear cell adenocarcinoma: A case report. ( 26082939 )	Ikeda Y....Fujii T.	2014
44	Primary non-clear-cell adenocarcinoma of the vagina in a diethylstilbestrol exposed woman. ( 24690973 )	Patel S.A....Sunde J.	2014
45	Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma simulating fetal gut in a postmenopausal woman. ( 24707459 )	Morimoto A....Fujiwara K.	2014
46	Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary. ( 25010038 )	Suzuki K....Okamoto A.	2014
47	Therapy of a clear cell adenocarcinoma of unknown primary arising in the abdominal wall after cesarean section and after hysterectomy. ( 25301100 )	Aust S....Langer M.	2014
48	A case of clear cell adenocarcinoma arising from endometriosis of the rectum treated by laparoscopic surgery. ( 25460452 )	Okazawa Y....Sakamoto K.	2014
49	Clear cell adenocarcinoma present exclusively within endometrial polyp: report of two cases. ( 24817975 )	Ishida M....Okabe H.	2014
50	Clear Cell Adenocarcinoma of the Urethra: 18F-FDG PET/CT Imaging. ( 25140553 )	Nguyen B.D.	2014

Sources

Genes for Clear Cell Adenocarcinoma

Genes related to Clear Cell Adenocarcinoma (0 elite genes):

(show all 13)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	KLK3	Kallikrein Related Peptidase 3	Protein Coding	26.02	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	7536368 9865832 7645457 (more) 11251541 7512941
2	MUC16	Mucin 16, Cell Surface Associated	Protein Coding	25.38	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	9234924 17713092
3	SMAD4	SMAD Family Member 4	Protein Coding	24.98	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	16820918
4	SMAD3	SMAD Family Member 3	Protein Coding	24.79	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	16820918
5	PTHLH	Parathyroid Hormone Like Hormone	Protein Coding	23.42	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	10637074
6	HNF1B	HNF1 Homeobox B	Protein Coding	22.97	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	KRT7	Keratin 7	Protein Coding	22.72	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	KRT20	Keratin 20	Protein Coding	22.1	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	PAX2	Paired Box 2	Protein Coding	21.71	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	SMAD2	SMAD Family Member 2	Protein Coding	21.64	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	16820918
11	ARID1A	AT-Rich Interaction Domain 1A	Protein Coding	21.63	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	PAX8	Paired Box 8	Protein Coding	21.39	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	AMACR	Alpha-Methylacyl-CoA Racemase	Protein Coding	21.35	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Clear Cell Adenocarcinoma

Copy number variations for Clear Cell Adenocarcinoma from CNVD:

⁷

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	218693	7	116312458	116438439	Amplification	MET	Clear cell adenocarcinoma
2	266962	Y	174481503	174538309	Duplication	AZF	Clear cell adenocarcinoma

Sources

Expression for Clear Cell Adenocarcinoma

Search GEO for disease gene expression data for Clear Cell Adenocarcinoma.

Sources

Pathways for Clear Cell Adenocarcinoma

Pathways related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 37)

#	Super pathways	Score	Top Affiliating Genes
1	Developmental Biology ⁶⁶ Show member pathways Axon guidance ⁶⁶	13.35	HNF1B KRT20 KRT7 SMAD2 SMAD3 SMAD4
2	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.64	KLK3 PAX8 SMAD2 SMAD3 SMAD4
3	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.62	ARID1A SMAD2 SMAD3 SMAD4
4	Pathways in cancer ³⁷	12.6	KLK3 PAX8 SMAD2 SMAD3 SMAD4
5	Human Embryonic Stem Cell Pluripotency ⁶⁴ Show member pathways Factors Promoting Cardiogenesis in Vertebrates ⁶⁴	12.31	HNF1B SMAD2 SMAD3 SMAD4
6	Mesodermal Commitment Pathway ¹ Show member pathways Endoderm Differentiation ¹	12.14	HNF1B PTHLH SMAD2 SMAD3 SMAD4
7	Cell cycle Role of SCF complex in cell cycle regulation ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Regulation of G1/S transition (part 1) ²² Immune response MIF-JAB1 signaling ²²	12.09	SMAD2 SMAD3 SMAD4
8	Colorectal Cancer Metastasis ⁶⁴	12.05	SMAD2 SMAD3 SMAD4
9	Hippo signaling pathway ³⁷	12.01	SMAD2 SMAD3 SMAD4
10	Signaling pathways regulating pluripotency of stem cells ³⁷	11.96	SMAD2 SMAD3 SMAD4
11	FoxO signaling pathway ³⁷ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	11.95	SMAD2 SMAD3 SMAD4
12	Apelin signaling pathway ³⁷	11.95	SMAD2 SMAD3 SMAD4
13	SMAD Signaling Network ⁶⁴	11.93	SMAD2 SMAD3 SMAD4
14	TGF-beta Signaling Pathway (WikiPathways) ¹	11.93	SMAD2 SMAD3 SMAD4
15	Wnt / Hedgehog / Notch ⁴	11.93	PAX2 SMAD2 SMAD3 SMAD4
16	Th1 Differentiation Pathway ⁶⁵ Show member pathways IL27-mediated signaling events ¹ Th17 Differentiation Pathway ⁶⁵	11.91	SMAD2 SMAD3 SMAD4
17	AGE-RAGE signaling pathway in diabetic complications ³⁷	11.78	SMAD2 SMAD3 SMAD4
18	TGF-beta Signaling Pathways ⁶⁵	11.76	SMAD2 SMAD3 SMAD4
19	Cytokine production by Th17 cells in CF (Mouse model) ²² Show member pathways Cytokine production by Th17 cells in CF ²²	11.74	SMAD2 SMAD3 SMAD4
20	Androgen receptor signaling pathway ¹	11.72	KLK3 SMAD3 SMAD4
21	TGF-beta signaling pathway (KEGG) ³⁷	11.68	SMAD2 SMAD3 SMAD4
22	Loss of Function of SMAD2/3 in Cancer ⁶⁶ Show member pathways BMP Signalling Pathway ¹ Canonical and Non-Canonical TGF-B signaling ¹ Loss of Function of SMAD4 in Cancer ⁶⁶ Loss of Function of TGFBR1 in Cancer ⁶⁶ Loss of Function of TGFBR2 in Cancer ⁶⁶ SMAD2/3 MH2 Domain Mutants in Cancer ⁶⁶ SMAD2/3 Phosphorylation Motif Mutants in Cancer ⁶⁶ SMAD4 MH2 Domain Mutants in Cancer ⁶⁶ TGFBR1 KD Mutants in Cancer ⁶⁶ TGFBR1 LBD Mutants in Cancer ⁶⁶ TGFBR2 Kinase Domain Mutants in Cancer ⁶⁶ TGFBR2 MSI Frameshift Mutants in Cancer ⁶⁶	11.62	SMAD2 SMAD3 SMAD4
23	Regulation of nuclear SMAD2/3 signaling ¹	11.61	SMAD2 SMAD3 SMAD4
24	Transcription_P53 signaling pathway ²²	11.57	SMAD2 SMAD3 SMAD4
25	Adherens junction ³⁷	11.57	SMAD2 SMAD3 SMAD4
26	Development_TGF-beta receptor signaling ²²	11.56	SMAD2 SMAD3 SMAD4
27	TGF-beta receptor signaling activates SMADs ⁶⁶ Show member pathways Downregulation of TGF-beta receptor signaling ⁶⁶ Signaling by TGF-beta Receptor Complex in Cancer ⁶⁶	11.53	SMAD2 SMAD3 SMAD4
28	IL-2 Gene Expression in Activated and Quiescent T-Cells ⁶⁴ Show member pathways TOB in T-Cell Signaling ⁶⁴	11.48	SMAD2 SMAD3 SMAD4
29	TGF-beta Receptor Signaling (WikiPathways) ¹	11.4	SMAD2 SMAD3 SMAD4
30	TGF-beta receptor signaling (Pathway Interaction Database) ¹	11.32	SMAD2 SMAD3 SMAD4
31	Signaling by NODAL ⁶⁶ Show member pathways Antagonism of Activin by Follistatin ⁶⁶ Regulation of signaling by NODAL ⁶⁶ Signaling by Activin ⁶⁶	11.28	SMAD2 SMAD3 SMAD4
32	NTHi-Induced Signaling ⁶⁴	10.97	SMAD3 SMAD4
33	Extracellular vesicle-mediated signaling in recipient cells ¹	10.97	SMAD2 SMAD3 SMAD4
34	ID signaling pathway ¹	10.82	PAX2 PAX8
35	Hypothesized Pathways in Pathogenesis of Cardiovascular Disease ¹	10.73	SMAD2 SMAD3 SMAD4
36	Regulation of cytoplasmic and nuclear SMAD2/3 signaling ¹	10.41	SMAD2 SMAD3 SMAD4
37	TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition ¹	10.05	SMAD2 SMAD3 SMAD4

Sources

GO Terms for Clear Cell Adenocarcinoma

Cellular components related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nuclear chromatin	GO:0000790	9.62	ARID1A SMAD2 SMAD3 SMAD4
2	transcription factor complex	GO:0005667	9.56	HNF1B SMAD2 SMAD3 SMAD4
3	activin responsive factor complex	GO:0032444	9.16	SMAD2 SMAD4
4	heteromeric SMAD protein complex	GO:0071144	8.96	SMAD2 SMAD3
5	SMAD protein complex	GO:0071141	8.8	SMAD2 SMAD3 SMAD4

Biological processes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 48)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription, DNA-templated	GO:0045893	9.95	ARID1A HNF1B PAX2 PAX8 SMAD2 SMAD3
2	kidney development	GO:0001822	9.85	HNF1B PAX8 SMAD4
3	anterior/posterior pattern specification	GO:0009952	9.84	HNF1B SMAD2 SMAD4
4	transforming growth factor beta receptor signaling pathway	GO:0007179	9.83	SMAD2 SMAD3 SMAD4
5	SMAD protein signal transduction	GO:0060395	9.79	SMAD2 SMAD3 SMAD4
6	positive regulation of epithelial to mesenchymal transition	GO:0010718	9.75	SMAD2 SMAD3 SMAD4
7	branching involved in ureteric bud morphogenesis	GO:0001658	9.74	PAX2 PAX8 SMAD4
8	pancreas development	GO:0031016	9.7	HNF1B SMAD2
9	thyroid gland development	GO:0030878	9.7	PAX8 SMAD3
10	adrenal gland development	GO:0030325	9.7	SMAD2 SMAD3
11	embryonic pattern specification	GO:0009880	9.69	SMAD2 SMAD3
12	signal transduction involved in regulation of gene expression	GO:0023019	9.69	SMAD2 SMAD3
13	osteoblast development	GO:0002076	9.69	PTHLH SMAD3
14	positive regulation of branching involved in ureteric bud morphogenesis	GO:0090190	9.68	PAX2 PAX8
15	activin receptor signaling pathway	GO:0032924	9.68	SMAD2 SMAD3
16	urogenital system development	GO:0001655	9.68	PAX2 PAX8
17	secondary palate development	GO:0062009	9.67	SMAD2 SMAD4
18	mesonephros development	GO:0001823	9.67	PAX2 PAX8
19	nodal signaling pathway	GO:0038092	9.65	SMAD2 SMAD3
20	primary miRNA processing	GO:0031053	9.65	SMAD2 SMAD3
21	embryonic foregut morphogenesis	GO:0048617	9.65	SMAD2 SMAD3
22	pericardium development	GO:0060039	9.64	SMAD2 SMAD3
23	mesenchymal to epithelial transition involved in metanephros morphogenesis	GO:0003337	9.63	PAX2 PAX8
24	mesonephric tubule development	GO:0072164	9.63	HNF1B PAX8
25	developmental growth	GO:0048589	9.63	SMAD2 SMAD3 SMAD4
26	regulation of metanephric nephron tubule epithelial cell differentiation	GO:0072307	9.62	PAX2 PAX8
27	metanephric epithelium development	GO:0072207	9.61	PAX2 PAX8
28	metanephric distal convoluted tubule development	GO:0072221	9.61	PAX2 PAX8
29	regulation of transforming growth factor beta receptor signaling pathway	GO:0017015	9.61	SMAD2 SMAD3 SMAD4
30	metanephric nephron tubule formation	GO:0072289	9.6	PAX2 PAX8
31	positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis	GO:0072108	9.59	PAX2 PAX8
32	regulation of transforming growth factor beta2 production	GO:0032909	9.58	SMAD3 SMAD4
33	nephric duct formation	GO:0072179	9.56	HNF1B PAX2
34	gastrulation	GO:0007369	9.56	ARID1A SMAD2 SMAD3 SMAD4
35	negative regulation of apoptotic process involved in metanephric collecting duct development	GO:1900215	9.55	PAX2 PAX8
36	negative regulation of apoptotic process involved in metanephric nephron tubule development	GO:1900218	9.54	PAX2 PAX8
37	SMAD protein complex assembly	GO:0007183	9.54	SMAD2 SMAD3 SMAD4
38	negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis	GO:0072305	9.52	PAX2 PAX8
39	paraxial mesoderm morphogenesis	GO:0048340	9.51	SMAD2 SMAD3
40	pronephros development	GO:0048793	9.5	HNF1B PAX2 PAX8
41	positive regulation of metanephric DCT cell differentiation	GO:2000594	9.49	PAX2 PAX8
42	pronephric field specification	GO:0039003	9.48	PAX2 PAX8
43	endoderm development	GO:0007492	9.46	HNF1B SMAD2 SMAD3 SMAD4
44	regulation of binding	GO:0051098	9.13	SMAD2 SMAD3 SMAD4
45	negative regulation of mesenchymal cell apoptotic process involved in metanephros development	GO:1900212	8.8	HNF1B PAX2 PAX8
46	positive regulation of transcription by RNA polymerase II	GO:0045944	10.11	HNF1B PAX2 PAX8 SMAD2 SMAD3 SMAD4
47	negative regulation of transcription by RNA polymerase II	GO:0000122	10.08	ARID1A HNF1B SMAD2 SMAD3 SMAD4
48	negative regulation of cell proliferation	GO:0008285	10	PTHLH SMAD2 SMAD3 SMAD4

Molecular functions related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 14)

#	Name	GO ID	Score	Top Affiliating Genes
1	DNA-binding transcription factor activity	GO:0003700	9.89	HNF1B PAX8 SMAD2 SMAD3 SMAD4
2	DNA-binding transcription factor activity, RNA polymerase II-specific	GO:0000981	9.87	ARID1A HNF1B PAX2 PAX8 SMAD2 SMAD3
3	protein heterodimerization activity	GO:0046982	9.84	HNF1B SMAD2 SMAD3 SMAD4
4	RNA polymerase II proximal promoter sequence-specific DNA binding	GO:0000978	9.81	PAX8 SMAD2 SMAD3 SMAD4
5	DNA-binding transcription activator activity, RNA polymerase II-specific	GO:0001228	9.7	SMAD2 SMAD3 SMAD4
6	enhancer binding	GO:0035326	9.46	SMAD2 SMAD3
7	co-SMAD binding	GO:0070410	9.43	SMAD2 SMAD3
8	I-SMAD binding	GO:0070411	9.4	SMAD2 SMAD4
9	primary miRNA binding	GO:0070878	9.37	SMAD2 SMAD3
10	transcription regulatory region DNA binding	GO:0044212	9.35	HNF1B PAX2 PAX8 SMAD3 SMAD4
11	R-SMAD binding	GO:0070412	9.33	SMAD2 SMAD3 SMAD4
12	transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity	GO:0030618	9.26	SMAD2 SMAD3
13	proximal promoter sequence-specific DNA binding	GO:0000987	8.92	HNF1B PAX2 SMAD3 SMAD4
14	DNA binding	GO:0003677	10.02	ARID1A HNF1B PAX2 PAX8 SMAD2 SMAD3

Sources

Sources for Clear Cell Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia